VPC-70063

• Description :

  VPC-70063 is a potent Myc-Max inhibitor with an IC50 value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; c-Myc; PARP

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vpc-70063.html

• Purity :

  99.92

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  FC(F)(C1=CC(NC(NCC2=CC=CC=C2)=S)=CC(C(F)(F)F)=C1)F

• Molecular Formula :

  C16H12F6N2S

• Molecular Weight :

  378.34

• References & Citations :

  [1]Carabet LA, et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem. 2018 Dec 5;160:108-119.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [13571-44-3]